Tilray Brands Inc (TLRY)

⭐ 1. Trump administration moved to reclassify cannabis to Schedule III
This is the biggest positive cannabis news connected to Trump in years.

The Trump administration initiated a major federal shift by moving cannabis from Schedule I ? Schedule III, recognizing medical use and easing restrictions.

This change expands medical research, opens banking pathways, and removes IRS 280E restrictions for cannabis businesses.

DOJ announced that FDA-approved marijuana products and state-licensed medical marijuana products are now placed in Schedule III immediately.

An expedited federal hearing is scheduled to consider broader rescheduling.

Why this is positive:
It’s the largest federal cannabis policy shift in decades, enabling research, lowering tax burdens, and improving industry stability.

⭐ 2. Trump’s executive order expanded medical marijuana & CBD research
Trump issued an Executive Order (Dec 18, 2025) directing agencies to expand research into medical marijuana and cannabidiol.

DOJ and DEA actions were explicitly framed as delivering on Trump’s promise to expand medical access and research.

Why this is positive:
It signals White House-level support for medical cannabis research and regulatory modernization.

⭐ 3. California cannabis regulators implementing rules to benefit businesses under Trump’s rescheduling
California’s Department of Cannabis Control proposed emergency rules to help businesses take advantage of federal benefits created by Trump’s rescheduling move.

Why this is positive:
States are already adjusting regulations to align with Trump’s federal changes, which could streamline licensing and compliance.

⭐ 4. Federal recognition of state-regulated medical marijuana programs
DOJ acknowledged the legitimacy of state medical marijuana systems, integrating them into the new Schedule III framework.

Why this is positive:
This reduces federal-state conflict and gives medical cannabis programs greater legal stability.

⭐ 5. Older adults increasingly turning to cannabis for medical use
While not directly Trump-driven, this trend is happening after the administration’s rescheduling move:

A federally funded AMA study found older adults are increasingly using cannabis as an alternative to pharmaceuticals.

Why this is positive:
It shows growing mainstream acceptance of cannabis for medical purposes.

⭐ 6. Federal study shows cannabis legalization reduces opioid poisonings
A federally funded study found marijuana legalization is associated with significant reductions in non-fatal opioid poisonings.

Why this is positive:
Supports the argument that cannabis access has public-health benefits, strengthening the case for reform.

⭐ 7. Trump’s rescheduling move is prompting states to modernize cannabis rules
Examples include:

California’s emergency rules (mentioned above).

Oklahoma requiring DEA registration for medical cannabis businesses to align with federal changes.

Why this is positive:
Federal action is pushing states toward more consistent, regulated, and legitimized cannabis markets. $TLRY

$TLRY Tilray is active across a broad set of international cannabis markets. Based on verified sources, the countries and regions involved include Canada, Europe (multiple countries), Australia, New Zealand, and Latin America, with specific production or distribution hubs in Germany, Portugal, and the United Kingdom.

🌍 Key Regions Where Tilray Operates
Each region below is a country or market where Tilray has either cultivation, production, distribution, or export activity.

Canada — Tilray’s original base and one of its largest production footprints, including major facilities like Aphria One and Aphria Diamond.

Europe — A major strategic region with EU-GMP facilities in Portugal and Germany, plus operations in the United Kingdom, and distribution into countries such as Poland and Italy.

Australia — Part of Tilray’s medical cannabis export network.

New Zealand — Included in Tilray’s Asia-Pacific footprint.

Latin America — Tilray exports medical cannabis products into multiple Latin American markets.

🇪🇺 Why Europe Is Considered the “Sleeping Giant”
Europe is poised for major cannabis expansion due to:

Large population and growing medical cannabis demand

Increasing acceptance and regulatory movement toward broader legalization

Tilray’s early investment in EU-GMP facilities in Portugal and Germany, giving it a compliant supply chain ready for scale

Tilray has explicitly positioned itself to lead once broader EU legalization occurs.

Banking reform progress — Efforts toward federal cannabis banking reform are improving access to institutional capital $TLRY

Federal rescheduling momentum — 96% of surveyed institutional investors expect cannabis to be moved to Schedule III during Trump’s term. $TLRY

2018 Farm Bill & Hemp Legalization
During his earlier term, Trump signed the 2018 Farm Bill, federally legalizing hemp and hemp-derived products. This triggered explosive growth in the CBD market and created new agricultural and manufacturing opportunities. $TLRY

$TLRY Expanding Medical Marijuana Research
The executive order instructs federal agencies to improve research methods, enabling more real-world evidence on cannabis and CBD. This is expected to help doctors better understand dosing, safety, and treatment outcomes.

$TLRY $MJ $TOKE ⭐ 1. Trump administration moved to reclassify cannabis to Schedule III
This is the biggest positive cannabis news connected to Trump in years.

The Trump administration initiated a major federal shift by moving cannabis from Schedule I ? Schedule III, recognizing medical use and easing restrictions.

This change expands medical research, opens banking pathways, and removes IRS 280E restrictions for cannabis businesses.

DOJ announced that FDA-approved marijuana products and state-licensed medical marijuana products are now placed in Schedule III immediately.

An expedited federal hearing is scheduled to consider broader rescheduling.

Why this is positive:
It’s the largest federal cannabis policy shift in decades, enabling research, lowering tax burdens, and improving industry stability.

⭐ 2. Trump’s executive order expanded medical marijuana & CBD research
Trump issued an Executive Order (Dec 18, 2025) directing agencies to expand research into medical marijuana and cannabidiol.

DOJ and DEA actions were explicitly framed as delivering on Trump’s promise to expand medical access and research.

Why this is positive:
It signals White House-level support for medical cannabis research and regulatory modernization.

⭐ 3. California cannabis regulators implementing rules to benefit businesses under Trump’s rescheduling
California’s Department of Cannabis Control proposed emergency rules to help businesses take advantage of federal benefits created by Trump’s rescheduling move.

Why this is positive:
States are already adjusting regulations to align with Trump’s federal changes, which could streamline licensing and compliance.

⭐ 4. Federal recognition of state-regulated medical marijuana programs
DOJ acknowledged the legitimacy of state medical marijuana systems, integrating them into the new Schedule III framework.

Why this is positive:
This reduces federal-state conflict and gives medical cannabis programs greater legal stability.

⭐ 5. Older adults increasingly turning to cannabis for medical use
While not directly Trump-driven, this trend is happening after the administration’s rescheduling move:

A federally funded AMA study found older adults are increasingly using cannabis as an alternative to pharmaceuticals.

Why this is positive:
It shows growing mainstream acceptance of cannabis for medical purposes.

⭐ 6. Federal study shows cannabis legalization reduces opioid poisonings
A federally funded study found marijuana legalization is associated with significant reductions in non-fatal opioid poisonings.

Why this is positive:
Supports the argument that cannabis access has public-health benefits, strengthening the case for reform.

⭐ 7. Trump’s rescheduling move is prompting states to modernize cannabis rules
Examples include:

California’s emergency rules (mentioned above).

Oklahoma requiring DEA registration for medical cannabis businesses to align with federal changes.

Why this is positive:
Federal action is pushing states toward more consistent, regulated, and legitimized cannabis markets.

$TLRY 🚀 The Tilray Bull Case — 🔥🌿
1. Cannabis Isn’t a Trend — It’s a Global Legalization Supercycle
Cannabis is marching toward legalization the same way alcohol did a century ago — slowly, then suddenly.

🌍 Macro tailwinds are lining up:

🇺🇸 U.S. rescheduling momentum is the strongest it’s ever been

🏛️ Bipartisan support for banking reform is growing

🌐 Global legalization expanding across Europe + LATAM

💰 Billions in tax revenue incentives for governments

📈 Consumer demand rising across medical + adult-use markets

This isn’t a maybe — it’s a global regulatory megatrend.

2. Tilray Is One of the Only Truly Global Cannabis Companies
Most cannabis companies are regional.
Tilray? Tilray is international.

🌎 Global footprint includes:

Canada

U.S. (via CPG + alcohol)

Europe

Australia

LATAM

Tilray has distribution, infrastructure, and regulatory positioning that most competitors can’t touch.

3. Tilray’s Diversification Is a Strategic Moat
Tilray isn’t just a cannabis company — it’s a multi-platform consumer powerhouse.

🔥 Diversified revenue streams include:

Cannabis

Medical cannabis

Hemp

Wellness

Craft beer

Beverages

CPG brands

This diversification gives Tilray something rare in the sector: stability + optionality.

4. The Alcohol Portfolio Is a Hidden Growth Engine
Tilray quietly became one of the largest craft-beer players in the U.S.

🍺 Why this matters:

Alcohol is a $200B+ market

Strong margins

National distribution

Cross-branding opportunities with cannabis

A platform for future THC beverages when regulations allow

This is a long-term Trojan horse into the U.S. cannabis market.

5. Tilray Is Positioned for U.S. Legalization Without Touching THC
Tilray has built a U.S. presence without violating federal law.

🧩 Strategic advantages:

Alcohol distribution

Hemp + wellness brands

CPG infrastructure

Retail relationships

Ability to flip the switch when legalization hits

When U.S. federal reform happens, Tilray is already in the building.

6. Europe Is Tilray’s Secret Weapon
While everyone watches the U.S., Europe is quietly becoming the world’s largest medical cannabis market.

🇪🇺 Tilray’s European advantages:

EU-GMP facilities

Medical distribution across multiple countries

First-mover advantage

Regulatory tailwinds

Potential for adult-use expansion

Tilray is one of the few companies positioned to dominate Europe.

7. Cannabis Touches Multiple Multi-Billion-Dollar Markets
Cannabis isn’t one industry — it’s a constellation of industries.

🚀 Tilray has exposure to:

Medical cannabis

Adult-use cannabis

Beverages

Wellness

Hemp

Pharmaceuticals

THC beverages (future)

CBD products

International medical markets

Each vertical is a massive opportunity on its own.

8. Tilray’s Valuation Is Crushed vs. Its Long-Term Optionality
Tilray is priced like the cannabis industry is dead — which is exactly why bulls see asymmetric upside.

💥 Why the setup is compelling:

Market cap deeply discounted

Cannabis sentiment near cycle lows

High short interest = potential squeeze fuel

Any regulatory progress could re-rate the entire sector

Diversified revenue reduces downside risk

This is the classic “left-for-dead” setup that contrarians love.

9. Tilray Is Cutting Costs + Focusing on Profitability
Execution is improving — and that’s where the upside begins.

📊 Operational improvements include:

Cost reductions

Streamlined operations

Better capital allocation

Margin expansion in alcohol + CPG

Focus on sustainable growth

Even moderate execution improvements could shift sentiment dramatically.

10. Cannabis Legalization Is Inevitable
The world is moving toward cannabis legalization — slowly, then all at once.

🔑 Why cannabis is a must:

Massive tax revenue potential

Strong public support

Medical benefits gaining recognition

Criminal justice reform momentum

Global regulatory convergence

Cannabis is a when, not an if — and Tilray is positioned to ride the wave.

$TLRY 🌱 is aligned with global trends toward legalization, wellness, and plant-based therapeutics, giving it long-term structural tailwinds.

$TLRY 🤝 is forming strategic partnerships across pharma, wellness, and consumer packaged goods to expand product lines and distribution.

$TLRY 🤝 is forming strategic partnerships across pharma, wellness, and consumer packaged goods to expand product lines and distribution.

$TLRY 🔥 is a high-short-interest stock with the potential for explosive upside when sentiment flips or catalysts hit.

$TLRY 💊 is a leader in medical cannabis with strong demand from patients and growing acceptance from healthcare systems worldwide.

$TLRY 🌍 is building a global distribution network across Europe, Canada, Australia, and Latin America, giving it unmatched international reach.

$TLRY 🇩🇪 is positioned to benefit massively from Germany’s cannabis legalization wave as Europe becomes the world’s largest regulated market.

$TLRY 🍺 is rapidly expanding its alcohol portfolio with brands like SweetWater and Montauk, giving it real revenue outside cannabis.

$TLRY 🌿 is one of the largest global cannabis companies with diversified revenue across cannabis, beverages, wellness, and medical markets.

$TLRY Most Credible Bullish Factors
Diversified revenue: Cannabis + alcohol (SweetWater, Montauk) + wellness products.

Largest global cannabis footprint: Operations in Canada, EU, and U.S. alcohol markets.

U.S. cannabis reform momentum: Rescheduling to Schedule III would reduce taxes and expand profitability.

European medical cannabis leadership: Germany’s legalization boosts demand.

Cost-cutting progress: TLRY has repeatedly reduced operating expenses.

Brand portfolio strength: SweetWater is one of the largest craft brewers in the U.S.

$TLRY Most Credible Bullish Factors
Diversified revenue: Cannabis + alcohol (SweetWater, Montauk) + wellness products.

Largest global cannabis footprint: Operations in Canada, EU, and U.S. alcohol markets.

U.S. cannabis reform momentum: Rescheduling to Schedule III would reduce taxes and expand profitability.

European medical cannabis leadership: Germany’s legalization boosts demand.

Cost-cutting progress: TLRY has repeatedly reduced operating expenses.

Brand portfolio strength: SweetWater is one of the largest craft brewers in the U.S.

And, 27 million cash positive (rev/debt).

$TLRY Tilray (TLRY) has Cash & equivalents: $204.6M

The CEO got to resign, Irwin Simon damaging investors.

Watching. Probably get back in at some point, in no rush

*This will go lower,

I think in the medical, R&D space, it is better. Especially the data repository from Tilray's early entrance and of course, the amount of product that can be leveraged for clinical trials. Unfortunately, we're probably a year out from realizing this advantage. Did you jump back in or are you still waiting? Absent any material news, this will to lower.

TLRY is now at .59 pre-split. Just goes to show ya, bigger isn’t always better…

$TLRY is positioning XMG+ as a performance-lifestyle product, targeting the same high-engagement consumer base that made $CELH a monster. Celsius proved how big this category can get — Tilray entering that lane opens a whole new growth vector.

🚀 1. Tilray Is One of the Only Truly Global Cannabis Companies
Tilray operates in:

Canada

United States

Europe

Australia

Latin America

Most cannabis companies are regional.
Tilray is international — and that’s a massive advantage as global legalization accelerates.

🌍 2. Tilray Has the Largest Global Cannabis Footprint
Tilray has:

EU-GMP certified facilities

Distribution across multiple continents

Medical cannabis operations in Europe

Recreational operations in Canada

Strategic U.S. assets ready for federal reform

This global infrastructure is extremely difficult for competitors to replicate.

🍺 3. Tilray Is Quietly Becoming a Major U.S. Beverage Player
Tilray owns or controls:

SweetWater Brewing

Montauk Brewing

Alpine Beer

Green Flash

Breckenridge Distillery

This gives Tilray:

U.S. revenue

U.S. distribution

U.S. shelf space

U.S. brand presence

All BEFORE cannabis becomes federally legal.

🧩 4. Tilray’s Beverage Strategy Is a Genius Trojan Horse
When U.S. legalization hits, Tilray already has:

Breweries

Distilleries

Distribution networks

Retail relationships

Manufacturing capacity

They can flip the switch and instantly launch THC beverages nationwide.

💊 5. Tilray Is a Leader in Medical Cannabis in Europe
Europe is the next big cannabis market.
Tilray is already:

EU-GMP certified

Selling medical cannabis in multiple countries

Positioned for German adult-use expansion

Building relationships with pharmacies and regulators

This is a multi-billion-dollar opportunity.

🧱 6. Tilray Has a Diversified Revenue Model
Tilray generates revenue from:

Cannabis

Beverages

Wellness products

Hemp foods

Medical exports

International operations

This diversification gives Tilray stability and multiple growth engines.

🌱 7. Tilray Is One of the Largest Cannabis Producers in the World
Tilray has:

Massive cultivation capacity

Low-cost production

Scalable infrastructure

Strong supply chain control

This positions Tilray to dominate as demand grows.

🧪 8. Tilray Has Deep Pharmaceutical-Grade Expertise
Tilray’s EU-GMP certification means:

Pharmaceutical-grade quality

Access to medical markets

Ability to supply hospitals and pharmacies

High regulatory trust

This is a moat few cannabis companies have.

🏛️ 9. Tilray Is Perfectly Positioned for U.S. Federal Legalization
When legalization hits, Tilray already has:

U.S. brands

U.S. distribution

U.S. manufacturing

U.S. retail relationships

Tilray is one of the few Canadian LPs with a real U.S. strategy.

📦 10. Tilray Is Building a Consumer Packaged Goods Empire
Tilray’s portfolio includes:

Cannabis

Beverages

Wellness

Hemp foods

Lifestyle brands

This is a long-term, durable business model.

🧠 11. Tilray’s Management Team Is Battle-Tested
CEO Irwin Simon has:

Built billion-dollar consumer brands

Led large CPG companies

Executed major acquisitions

Navigated complex regulatory environments

This is the kind of leadership cannabis companies need.

🧨 12. Tilray Has Massive Asymmetric Upside
If:

U.S. legalizes

Europe expands

Cannabis beverages explode

Global markets open

…Tilray becomes one of the biggest players in the world.

🔥 13. Tilray Is a Pure Play on Global Cannabis Normalization
As more countries legalize:

Medical markets grow

Adult-use markets open

Export markets expand

Pharmaceutical demand increases

Tilray is positioned to benefit from every stage.

🌟 14. Tilray Has Strong Brand Power
Tilray owns or partners with:

Good Supply

Broken Coast

RIFF

SweetWater

Montauk

Breckenridge

These brands give Tilray cultural relevance and consumer loyalty.

🧩 15. Tilray Is Building the Infrastructure for the Next Decade
Tilray is investing in:

Manufacturing

Distribution

Global supply chains

Brand development

R&D

This is long-term, strategic positioning.

🚀 16. Tilray Is One of the Few Cannabis Companies With Real Scale
Scale matters in cannabis:

Lower costs

Better margins

Stronger distribution

More negotiating power

Tilray is already operating at global scale.

🌐 17. Tilray Is a Bet on the Entire Cannabis Megatrend
If you believe:

Cannabis will be federally legal

Cannabis beverages will explode

Europe will legalize

Global markets will open

Medical cannabis will expand

…then Tilray is one of the clearest, purest ways to express that view.

Good post. I am a consumer of these products and believe them to be a great alternative. The only that bothers me is the price. I’m in MN and $25-30 per 4 pack is ridiculous but not surprising in a blue state. Once this whole sector of THC drinks figures out a way to make them more affordable this will remain only available to certain people with disposable incomes. 

$TLRY 🥤 XMG (Flagship THC Beverage Line)

XMG is Tilray’s leading THC drink brand in Canada and the core of its cannabis beverage portfolio.

Typical products include:

XMG Cream Soda (10mg THC)
XMG Cherry Cola and Orange Soda (10mg THC)
XMG+ Tropical Cream Float (THC combined with CBG and caffeine)
XMG Atomic Sours (flavors like Cherry Lime and Foggy Peaches)

Most XMG beverages contain about 10mg of THC per can and are formulated for fast onset using nano-emulsified technology. The lineup is designed in familiar soda and energy drink formats, making it approachable for recreational use.

XMG is considered the dominant brand in Tilray’s beverage segment and ranks among the top-selling cannabis drink lines in the Canadian market.

🍺 Mollo (Alcohol Alternative Line)

Mollo is positioned as Tilray’s direct attempt to replace traditional alcohol with THC-based beverages.

Key examples include:

Mollo 10, a THC-infused lager-style drink (10mg THC)
Mollo Pineapple Seltzer (THC combined with CBG)
Mollo Orchard Chill’r, styled after cider-like drinks

These products are designed to replicate the taste and social experience of beer or cider, but with THC instead of alcohol. The goal is to offer a familiar drinking format while delivering a cannabis-induced effect rather than intoxication from alcohol.

🇺🇸 U.S. THC Beverages (Hemp-Derived Products)

Tilray is also expanding into the U.S. market through hemp-derived THC beverages, where regulations allow.

Key brands include:

Happy Flower, offering THC-infused cocktails such as margarita and bellini-style drinks
Fizzy Jane’s, a line of THC sparkling seltzers

These beverages typically contain around 5–10mg of delta-9 THC derived from hemp and are sold in select U.S. markets. Their formats closely resemble alcoholic beverages, such as cocktails and flavored seltzers.

🧠 Strategic Positioning

Tilray’s THC beverage portfolio is not just about cannabis drinks—it reflects a broader strategy to build a new category centered on alcohol replacement.

Each brand serves a specific role:

XMG focuses on fun, soda-style THC experiences
Mollo targets beer and cider substitution
Happy Flower and Fizzy Jane’s mimic cocktails and social alcohol drinks

The company is ultimately betting on the long-term shift toward “mindful drinking,” where consumers reduce alcohol consumption in favor of alternative intoxicating beverages like THC drinks.

I agree, cannabis has a strong future. People are sick of big pharma drugs that have side effects worse than the ailments. That's absolutely insane, and it's why people want better options like cannabis. However, big pharma is a very major industry and they have a lot of power in Washington and Wall Street and they aren't going down without a fight. They delayed re-scheduling for as long as they could and now they (along with dirty Wall Street institutions, dirty hedge funds and dirty market makers) are crushing the cannabis sector right after the biggest catalyst in cannabis history! It's criminal manipulation at the highest level. It's cartel level shit. They have no fear of any regulations, laws or government authority. They are sending the deadly message to any investor who wants to support the cannabis sector that they will be crushed! Those filthy criminals must be locked up!

The question is, how long can they keep it up? Despite what many people say, institutions CAN invest in cannabis while in Schedule 3. Also, the Democrats have stated that they will legalize cannabis so the Republicans will have to beat them to it, meaning that cannabis will be legalized in the next 2.5 years. I can wait that long.

🌍 Global Cannabis Market Value & Growth Outlook
📈 Explosive Market Expansion
Across multiple independent industry forecasts, the cannabis market is growing at double-digit to high-double-digit annual rates, depending on the segment and methodology.

Here are the most authoritative figures:

$102.7B global market value in 2025, projected to reach $1.43 trillion by 2034 at a 34% CAGR.

Another global model estimates $14.1B in 2024, growing to $70.17B by 2034 at 17.4% CAGR.

A third forecast projects $134B in 2026, rising to $831B by 2035 at a 34% CAGR.

Additional analysis shows $38B in 2025, expected to reach $179.9B by 2034 at 18.8% CAGR.

Another long-term model projects $38.8B in 2025 growing to $159.8B by 2035 at 15.2% CAGR.

Synthesis:
Even though methodologies differ, every major forecast agrees:
➡️ Cannabis is one of the fastest-growing global industries, with projected growth ranging from 15% to 34% annually over the next decade.

🌎 Where Demand Is Coming From
🇺🇸 North America Leads
North America accounts for 40–84% of global market share depending on the model.

The U.S. alone is projected to reach over $428B by 2032 in some forecasts.

Recreational use drives 52–56% of U.S. demand, while medical use accounts for 42–44%.

🇪🇺 Europe Rising
Europe contributes 25–28% of global growth.

Medical cannabis adoption is accelerating due to regulatory reforms and healthcare integration.

🌏 Asia-Pacific Emerging
Asia-Pacific accounts for 20–21% of global growth.

Thailand’s full decriminalization in 2022 accelerated regional momentum.

🌍 Middle East, Africa & Latin America
These regions collectively contribute 10% of global growth.

Many countries are legalizing medical cannabis and exploring cannabis-based economic development.

💡 What’s Driving Global Demand?
1️⃣ Legalization Momentum
Over 50+ countries now allow medical cannabis, and many are moving toward recreational frameworks.

2️⃣ Medical Adoption
Cannabis is increasingly used for:

chronic pain

neurological disorders

cancer-related symptoms

appetite stimulation

anxiety and sleep disorders

3️⃣ Consumer Wellness Trends
58% of consumers prefer natural cannabis-based wellness products.

Edibles, oils, and concentrates are rapidly growing categories.

4️⃣ Product Innovation
Growth in edibles, beverages, skincare, and pharmaceutical formulations.

30% of new innovation comes from edibles and skincare.

5️⃣ Economic Opportunity
Cannabis legalization boosts job creation and tax revenue.

Many countries view cannabis as a strategic agricultural and pharmaceutical sector.

🔮 Bottom Line
Global cannabis demand is accelerating, driven by legalization, medical acceptance, wellness trends, and product innovation. Depending on the model, the market is on track to reach $150B to over $1.4T within the next decade. $TLRY

The cannabis sector has some of the strongest long-term bullish forces of any emerging industry, driven by legalization momentum, massive consumer demand, and explosive market growth projections.

Below is a structured, deeply grounded, highly bullish outlook on cannabis stocks in general, with all claims supported by current industry data.

🌱 Why the Cannabis Sector Has Enormous Bullish Potential
1. Legalization Momentum Is Accelerating
The U.S. cannabis market is already enormous and is projected to grow at 11.5% annually through 2030, driven by expanding medical and recreational legalization.

Rescheduling efforts at the federal level have gained traction, with executive action pushing cannabis toward Schedule III, a shift industry leaders call a “game changer.”

More states are preparing to legalize adult-use markets, with large states like Florida and Pennsylvania expected to significantly boost national sales.

Bullish takeaway: Regulatory barriers are falling, and every new state that legalizes adds billions in potential revenue.

2. The Market Size Is Massive — and Growing Fast
The U.S. cannabis market was valued at $38.5 billion in 2024 and is projected to expand rapidly through 2030.

Global cannabis markets are even more explosive, expected to grow from $137.7 billion in 2026 to over $1.4 trillion by 2034 — a staggering 34% CAGR.

U.S. regulated cannabis sales alone are forecast to reach $39.1 billion by 2029.

Bullish takeaway: Few industries on Earth have trillion-dollar trajectories with this level of consumer demand and regulatory tailwinds.

3. Consumer Demand Is Deep, Diverse, and Expanding
Nearly half of U.S. adults have tried cannabis, reflecting broad cultural acceptance.

Demand spans medical, wellness, recreational, and specialty products — from flower to edibles to vapes to minor cannabinoids like CBN and CBG.

Pre-rolls and convenient formats are experiencing double-digit growth as mainstream consumers enter the market.

Bullish takeaway: Cannabis is no longer niche — it’s a normalized consumer category with accelerating adoption.

4. Medical Cannabis Is a Major Long-Term Growth Engine
Cannabis is increasingly used for chronic pain, chemotherapy-related nausea, and seizure disorders.

FDA-approved cannabis-derived medications (like Epidiolex) validate the plant’s therapeutic value.

As research expands, new medical applications will unlock additional multi-billion-dollar markets.

Bullish takeaway: Medical cannabis is still in early innings, with huge upside as clinical research expands.

5. Institutional Capital and Startups Are Flooding In
Major investment funds and private equity groups are deploying capital into cannabis infrastructure, cultivation, and retail.

Startups continue to raise large rounds, including $350 million+ financings for cannabis tech platforms.

Bullish takeaway: Smart money is positioning early for the next decade of growth.

6. International Legalization Is Creating a Global Opportunity
Countries across Europe, Asia, and Latin America are moving toward medical or recreational legalization.

Thailand’s full decriminalization of cannabis cultivation and consumption demonstrates how quickly markets can open and scale.

Bullish takeaway: Cannabis is becoming a global commodity, not just a U.S. trend.

🌿 Final Bullish Summary
The cannabis industry is supported by explosive market growth, broad consumer adoption, medical validation, and rapid legalization momentum. Despite short-term volatility, the long-term trajectory is unmistakably upward. The combination of regulatory reform, cultural acceptance, and trillion-dollar global potential makes cannabis one of the most compelling emerging sectors of the next decade. $TLRY

🌿🚀 300 Reasons Why $TLRY Is SUPER BULLISH

🌱 Tilray Is a Global Cannabis Powerhouse
TLRY is one of the largest cannabis companies in the world.

TLRY has global brand recognition.

TLRY operates in multiple countries.

TLRY has international distribution.

TLRY has medical cannabis operations.

TLRY has recreational cannabis operations.

TLRY has pharmaceutical-grade production.

TLRY has GMP-certified facilities.

TLRY has EU-GMP certification.

EU-GMP is the gold standard.

TLRY can export globally.

TLRY is positioned for worldwide legalization.

Global legalization is inevitable.

TLRY is early.

Early = massive upside.

TLRY is a first mover.

First movers dominate.

TLRY is building global infrastructure.

Infrastructure = long-term revenue.

TLRY is a global cannabis leader.

🍺 Tilray Owns a Massive Alcohol Portfolio
TLRY owns beer brands.

TLRY owns craft breweries.

TLRY owns beverage distribution.

TLRY owns SweetWater Brewing.

SweetWater is a top craft brand.

TLRY owns Montauk Brewing.

Montauk is a fast-growing brand.

TLRY owns Breckenridge Distillery.

TLRY owns multiple beverage assets.

TLRY is diversifying revenue.

Diversification = stability.

Alcohol is a huge market.

Alcohol is federally legal.

Alcohol generates cash flow.

TLRY’s alcohol segment is expanding.

TLRY is becoming a beverage powerhouse.

Cannabis + alcohol = synergy.

TLRY is positioned for infused beverages.

Infused beverages will be massive.

TLRY is ready to dominate that category.

🌍 Tilray Has Global Cannabis Distribution
TLRY exports to Europe.

TLRY exports to Australia.

TLRY exports to Latin America.

TLRY exports to Israel.

TLRY exports to international pharmacies.

TLRY has global supply chains.

TLRY has global logistics.

TLRY has global partnerships.

TLRY has global cultivation.

TLRY has global processing.

TLRY has global packaging.

TLRY has global compliance.

TLRY is everywhere cannabis is legal.

TLRY will be everywhere cannabis becomes legal.

Global legalization is accelerating.

TLRY is positioned to capture global demand.

Global demand is enormous.

TLRY’s TAM is global.

Global TAM = massive upside.

TLRY is a global cannabis giant.

💊 Tilray Dominates Medical Cannabis
TLRY supplies medical cannabis worldwide.

Medical cannabis demand is rising.

Doctors are prescribing cannabis more often.

Patients prefer natural treatments.

TLRY produces pharmaceutical-grade products.

TLRY has clinical-grade facilities.

TLRY has medical partnerships.

TLRY has research collaborations.

TLRY has medical distribution channels.

TLRY is trusted by physicians.

Medical cannabis is high-margin.

High-margin = high profitability.

TLRY is positioned for medical expansion.

Medical legalization is accelerating globally.

TLRY is the global medical leader.

Medical cannabis is a long-term megatrend.

TLRY is aligned with that megatrend.

Megatrends create massive winners.

TLRY is one of them.

TLRY is the medical cannabis brand of the future.

🇺🇸 Tilray Is Positioned for U.S. Legalization
U.S. legalization is inevitable.

TLRY is ready for it.

TLRY has U.S. infrastructure.

TLRY has U.S. distribution.

TLRY has U.S. beverage assets.

TLRY has U.S. brand recognition.

TLRY has U.S. partnerships.

TLRY has U.S. expansion plans.

TLRY will enter the U.S. cannabis market instantly.

TLRY will dominate infused beverages.

TLRY will dominate cannabis drinks.

TLRY will dominate cannabis edibles.

TLRY will dominate cannabis wellness.

TLRY will dominate cannabis retail.

TLRY will dominate cannabis branding.

TLRY will dominate cannabis distribution.

TLRY will dominate cannabis beverages.

TLRY will dominate cannabis lifestyle products.

TLRY is the U.S. legalization trade.

Legalization = rocket fuel.

🧪 Tilray Has Massive R&D Capabilities
TLRY invests heavily in research.

TLRY develops new strains.

TLRY develops new formulations.

TLRY develops new delivery methods.

TLRY develops new medical applications.

TLRY develops new consumer products.

TLRY’s R&D team is world-class.

TLRY’s innovation pipeline is strong.

Innovation drives adoption.

Adoption drives revenue.

Revenue drives valuation.

TLRY is innovating aggressively.

TLRY is creating next-gen cannabis products.

TLRY is creating next-gen beverages.

TLRY is creating next-gen wellness products.

TLRY is creating next-gen infused drinks.

TLRY is creating next-gen medical products.

TLRY is building the future of cannabis.

The future of cannabis is enormous.

TLRY is positioned to lead it.

🏭 Tilray Has Massive Production Capacity
TLRY has huge cultivation facilities.

TLRY has high-tech greenhouses.

TLRY has automated production.

TLRY has scalable operations.

TLRY has efficient processing.

TLRY has advanced extraction.

TLRY has pharmaceutical-grade labs.

TLRY has global supply chains.

TLRY has massive output potential.

TLRY can scale instantly.

Scaling = revenue growth.

Revenue growth = valuation growth.

TLRY’s infrastructure is unmatched.

TLRY’s production is world-class.

TLRY’s facilities are state-of-the-art.

TLRY’s capacity is expanding.

TLRY is ready for global demand.

Global demand is rising.

TLRY is positioned perfectly.

TLRY is built for scale.

🛒 Tilray Has Powerful Consumer Brands
TLRY owns multiple cannabis brands.

TLRY owns multiple beverage brands.

TLRY owns multiple wellness brands.

TLRY owns multiple lifestyle brands.

TLRY’s brands are growing.

TLRY’s brands are recognized.

TLRY’s brands are trusted.

TLRY’s brands are expanding.

TLRY’s brands appeal to young consumers.

TLRY’s brands appeal to wellness consumers.

TLRY’s brands appeal to recreational consumers.

TLRY’s brands appeal to medical consumers.

TLRY’s brands appeal to global consumers.

TLRY’s brand portfolio is diversified.

Diversification = stability.

Stability = long-term growth.

TLRY is building a consumer-goods empire.

Cannabis + beverages = unstoppable.

TLRY is the Procter & Gamble of cannabis.

TLRY is building a consumer powerhouse.

📈 Tilray Has Massive Growth Potential
Cannabis demand is rising.

Beverage demand is rising.

Wellness demand is rising.

Global legalization is rising.

Medical adoption is rising.

Recreational adoption is rising.

TLRY is positioned for all of it.

TLRY’s TAM is enormous.

TAM expansion = valuation expansion.

TLRY is early in its growth curve.

Early = asymmetric upside.

Asymmetric upside = moonshot potential.

TLRY is a long-term compounder.

Compounders create massive returns.

TLRY is a global growth story.

TLRY is a U.S. legalization story.

TLRY is a cannabis beverage story.

TLRY is a wellness story.

TLRY is a consumer-goods story.

TLRY is a multi-sector growth engine.

🌋 Tilray Is Positioned for Explosive Expansion
TLRY is expanding in Europe.

TLRY is expanding in the U.S.

TLRY is expanding in Canada.

TLRY is expanding in Australia.

TLRY is expanding in Latin America.

TLRY is expanding in Israel.

TLRY is expanding globally.

Expansion = revenue growth.

Revenue growth = valuation growth.

TLRY is scaling fast.

TLRY is acquiring brands.

TLRY is consolidating the industry.

TLRY is building a global empire.

TLRY is becoming a multinational giant.

TLRY is positioned for hypergrowth.

Hypergrowth = massive upside.

TLRY is a global cannabis titan.

TLRY is a global beverage titan.

TLRY is a global wellness titan.

TLRY is a global consumer titan.

🔮 Tilray Is Building the Future of Cannabis
The future is cannabis beverages.

TLRY is ready for that.

The future is cannabis wellness.

TLRY is ready for that.

The future is cannabis pharmaceuticals.

TLRY is ready for that.

The future is global legalization.

TLRY is ready for that.

The future is infused drinks.

TLRY is ready for that.

The future is cannabis tourism.

TLRY is ready for that.

The future is cannabis retail.

TLRY is ready for that.

The future is cannabis branding.

TLRY is ready for that.

The future is cannabis distribution.

TLRY is ready for that.

The future is cannabis consumer goods.

TLRY is ready for that.

🌠 Tilray’s Long-Term Potential Is Enormous
TLRY could dominate global cannabis.

TLRY could dominate infused beverages.

TLRY could dominate cannabis wellness.

TLRY could dominate cannabis pharma.

TLRY could dominate cannabis retail.

TLRY could dominate cannabis branding.

TLRY could dominate cannabis distribution.

TLRY could dominate cannabis beverages.

TLRY could dominate cannabis edibles.

TLRY could dominate cannabis lifestyle products.

TLRY could become a global giant.

TLRY could become a household name.

TLRY could become a consumer-goods empire.

TLRY could become a beverage empire.

TLRY could become a cannabis empire.

TLRY could become a multinational titan.

TLRY could become a generational company.

Generational companies create generational wealth.

TLRY is early.

Early = opportunity.

🌞 Tilray Is a Once-in-a-Generation Cannabis Company
TLRY is a global leader.

TLRY is diversified.

TLRY is innovative.

TLRY is expanding.

TLRY is scaling.

TLRY is acquiring.

TLRY is dominating.

TLRY is building.

TLRY is evolving.

TLRY is transforming.

TLRY is shaping the future.

TLRY is aligned with megatrends.

TLRY is aligned with legalization.

TLRY is aligned with wellness.

TLRY is aligned with beverages.

TLRY is aligned with global growth.

TLRY is aligned with consumer demand.

TLRY is aligned with the future.

TLRY is a future giant.

TLRY is a future empire.

🚀 Tilray Is a Multi-Sector Moonshot
Cannabis is a megatrend.

Beverages are a megatrend.

Wellness is a megatrend.

Global legalization is a megatrend.

TLRY is in all of them.

Multi-megatrend exposure = massive upside.

TLRY is a multi-sector disruptor.

Disruptors create massive returns.

TLRY is early in its disruption curve.

Early = asymmetric upside.

Asymmetric upside = moonshot.

TLRY is a moonshot.

Moonshots change industries.

TLRY will change cannabis.

TLRY will change beverages.

TLRY will change wellness.

TLRY will change consumer goods.

TLRY will change global markets.

TLRY is a global disruptor.

TLRY is a global innovator.

🌌 Tilray’s Story Is Just Beginning
TLRY is early-stage.

Early-stage = maximum upside.

TLRY is pre-legalization U.S. entry.

Pre-legalization = explosive potential.

TLRY is pre-infused beverage boom.

Pre-boom = massive runway.

TLRY is pre-global cannabis adoption.

Pre-adoption = exponential growth.

TLRY is pre-mainstream cannabis acceptance.

Pre-mainstream = generational upside.

TLRY is building infrastructure.

Infrastructure = long-term dominance.

TLRY is building brands.

Brands = long-term value.

TLRY is building global reach.

Global reach = global revenue.

TLRY is building the future.

The future is cannabis.

The future is beverages.

The future is TLRY — and that’s as bullish as it gets.

Why is all the Pot stocks down, I bought this morning at the higher price and purchased more at 6.94

RECLASSIFIED!!!

Marijuana reclassification to Schedule 3 ..... Happy belated 420!

$TLRY 🚀 **40 Ultra-Bullish Pillars for Tilray ($TLRY)**
*(All grounded in sourced facts; each can be expanded into 5–10 sub-reasons to reach 200.)*

### 🇨🇦 **1–10: Dominance in Canada (the world’s largest federally legal market)**
1. **#1 market share in Canada across multiple categories** including flower, pre-rolls, beverages, chocolate edibles, and oils. [The Motley Fool](https://www.fool.com/investing/2026/04/22/1-wall-street-analyst-says-tilray-stock-could-jump/)
2. **Canadian cannabis revenue up 8% YoY**, showing stability and growth. [The Motley Fool](https://www.fool.com/investing/2026/04/22/1-wall-street-analyst-says-tilray-stock-could-jump/)
3. **Strong brand portfolio** with leadership positions across THC categories.
4. **Regulatory moat** — Canada’s strict rules make it hard for new entrants.
5. **Tilray’s scale advantage** gives it superior distribution.
6. **Cost efficiencies** from Project 420. [Zacks Investment Research](https://www.zacks.com/stock/news/2822584/tilray-brands-bullish-beverage-strategy-whats-behind-the-optimism)
7. **45%+ THC beverage market share** — a massive moat. [Zacks Investment Research](https://www.zacks.com/stock/news/2822584/tilray-brands-bullish-beverage-strategy-whats-behind-the-optimism)
8. **Improved retail distribution** after 2025 resets. [Zacks Investment Research](https://www.zacks.com/stock/news/2822584/tilray-brands-bullish-beverage-strategy-whats-behind-the-optimism)
9. **Brand loyalty improving** as restrictions ease.
10. **Canadian leadership positions TLRY for U.S. entry** when allowed.

---

### 🌍 **11–20: Explosive International Growth**
11. **Record international cannabis revenue**, up **70% YoY**. [The Motley Fool](https://www.fool.com/investing/2026/04/22/1-wall-street-analyst-says-tilray-stock-could-jump/)
12. **International revenue now 37% of total** — diversifying away from Canada. [The Motley Fool](https://www.fool.com/investing/2026/04/22/1-wall-street-analyst-says-tilray-stock-could-jump/)
13. **Largest global medical cannabis footprint** among Canadian LPs.
14. **European medical cannabis expansion** accelerating.
15. **UK craft beer acquisition (BrewDog)** expands brand presence. [The Motley Fool](https://www.fool.com/investing/2026/04/22/1-wall-street-analyst-says-tilray-stock-could-jump/)
16. **Carlsberg partnership** accelerates global beverage scaling. [The Motley Fool](https://www.fool.com/investing/2026/04/22/1-wall-street-analyst-says-tilray-stock-could-jump/)
17. **MEA (Middle East & Africa) beverage expansion** underway. [Zacks Investment Research](https://www.zacks.com/stock/news/2822584/tilray-brands-bullish-beverage-strategy-whats-behind-the-optimism)
18. **Global distribution platform worth $300M** ready for U.S. medical entry. [24/7 Wall St.](https://247wallst.com/investing/2026/04/23/tilray-surges-10-rescheduling-momentum-builds-as-traders-await-official-confirmation/)
19. **Global medical cannabis TAM expanding rapidly**.
20. **Tilray positioned as a first-mover in multiple continents**.

---

### 🍺 **21–30: Beverage Empire = Hidden Growth Engine**
21. **Beverage revenue up 22% YoY** in latest quarter. [The Motley Fool](https://www.fool.com/investing/2026/04/22/1-wall-street-analyst-says-tilray-stock-could-jump/)
22. **Massive synergy potential** with Carlsberg.
23. **SweetWater, Shock Top, and other brands improving** after resets. [Zacks Investment Research](https://www.zacks.com/stock/news/2822584/tilray-brands-bullish-beverage-strategy-whats-behind-the-optimism)
24. **$27M annualized cost savings** from Project 420. [Zacks Investment Research](https://www.zacks.com/stock/news/2822584/tilray-brands-bullish-beverage-strategy-whats-behind-the-optimism)
25. **Non-alcoholic category expansion** (Runner’s High). [Zacks Investment Research](https://www.zacks.com/stock/news/2822584/tilray-brands-bullish-beverage-strategy-whats-behind-the-optimism)
26. **Beverages provide diversification** away from cannabis volatility.
27. **Beverage margins improving** with SKU rationalization.
28. **U.S. distribution footprint already built** for future THC beverages.
29. **Beverages create brand familiarity pre-legalization**.
30. **Beverage business alone could justify a higher valuation**.

---

### 🇺🇸 **31–40: U.S. Rescheduling = Massive Asymmetric Upside**
31. **Schedule III reclassification speculation already pumped TLRY 10–14%** in two days. [24/7 Wall St.](https://247wallst.com/investing/2026/04/23/tilray-surges-10-rescheduling-momentum-builds-as-traders-await-official-confirmation/)
32. **Federal tax advantages unlocked** under Schedule III. [24/7 Wall St.](https://247wallst.com/investing/2026/04/23/tilray-surges-10-rescheduling-momentum-builds-as-traders-await-official-confirmation/)
33. **Banking access improves**, lowering friction costs. [Invezz](https://invezz.com/news/2026/04/23/tilray-stock-price-soars-as-we-predicted-now-what/)
34. **Easier compliance ? higher earnings quality**. [Invezz](https://invezz.com/news/2026/04/23/tilray-stock-price-soars-as-we-predicted-now-what/)
35. **Tilray doesn’t even need U.S. THC sales to benefit** — optionality without risk. [Invezz](https://invezz.com/news/2026/04/23/tilray-stock-price-soars-as-we-predicted-now-what/)
36. **CEO Irwin Simon says rescheduling is “transformative.”** [24/7 Wall St.](https://247wallst.com/investing/2026/04/23/tilray-surges-10-rescheduling-momentum-builds-as-traders-await-official-confirmation/)
37. **Tilray already has a $150M global medical cannabis business** ready to plug into the U.S. market. [24/7 Wall St.](https://247wallst.com/investing/2026/04/23/tilray-surges-10-rescheduling-momentum-builds-as-traders-await-official-confirmation/)
38. **Analysts modeling >40% upside** (Roth Capital). [The Motley Fool](https://www.fool.com/investing/2026/04/22/1-wall-street-analyst-says-tilray-stock-could-jump/)
39. **Consensus rating: Strong Buy** with extreme upside targets (avg $72). [Stock Analysis](https://stockanalysis.com/stocks/tlry/forecast/)
40. **Asymmetric risk/reward** — downside limited, upside enormous.

looking good all the buys going on this will go 20$ + in the next month imo

nice reversal volume wowowowoo

🔥 Why $TLRY Could See a Short Squeeze
1. High Short-Interest Percentage (8.8%–12.4% of the float)
Recent datasets show that 8.86% of TLRY’s float is sold short as of November 2025 .
Another dataset shows 12.36% short interest as of March 2026 .

Anything above 10% is considered elevated, and TLRY frequently sits near or above that threshold.

This means a meaningful portion of traders are betting against the stock — a setup that can unwind quickly.

2. Days-to-Cover Is Rising (5.95–7.57 Days)
Days-to-cover (DTC) measures how long it would take shorts to exit if they all had to buy back shares.

5.95 days as of March 31, 2026

7.57 days in the February 27, 2026 FINRA report

A DTC above 5 is considered high.
A DTC above 7 is considered squeeze-prone.

This means shorts cannot exit quickly if buying pressure increases.

3. Borrow Fees Are Elevated (8–11%)
Borrow fees for TLRY have been consistently high, with recent readings around 8.65% and spikes above 10% .

High borrow fees indicate:

Shorting TLRY is expensive

Shorts are under pressure to close positions sooner

Any upward move can force covering

This is classic squeeze fuel.

4. TLRY Has a History of Short-Driven Volatility
Historical data shows periods where TLRY had:

17% short interest

5.2–7.0 days to cover

Massive volume spikes

These conditions have previously led to sharp upside moves, especially during cannabis-sector news cycles.
This pattern increases the probability of future squeezes.

Bloomberg just reported that US plans to ease restrictions on cannabis, as well. Multiple sources people!!

Canadian Investment Regulatory Organization Trade Resumption - TLRYApril 22, 2026 12:13 PM
PR Newswire (Canada)

TORONTO, April 22, 2026 /CNW/ - Trading resumes in: Company: Tilray Brands, Inc.TSX Symbol: TLRYAll Issues: NoResumption (ET): 11:54:38 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada..SOURCE Canadian Investment Regulatory Organization (CIRO) – Halts/Resumptions

Original: Canadian Investment Regulatory Organization Trade Resumption - TLRY

L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - TLRYApril 22, 2026 12:18 PM
PR Newswire (Canada)

TORONTO, le 22 avril 2026 /CNW/ - Reprise des négociations pour :Société : Tilray Brands, Inc.Symbole TSX : TLRYLes titres : NonReprise : 11h 54:38L'OCRI peut prendre la décision de suspendre (ou d'arrêter) temporairement les opérations à l'égard d'un titre d'une société cotée en bourse. Les arrêts des opérations sont mis en oeuvre afin d'assurer le bon fonctionnement d'un marché équitable. L'OCRI est l'organisme d'autoréglementation national qui surveille l'ensemble des courtiers en placement et l'ensemble des opérations effectuées sur les marchés des titres de capitaux propres et les marchés des titres de créance au Canada.SOURCE L’Organisme canadien de règlementation des investissements (OCRI) - Arrêts/Reprises

Original: L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - TLRY

Canadian Investment Regulatory Organization Trading Halt - TLRYApril 22, 2026 12:00 PM
PR Newswire (Canada)

TORONTO, April 22, 2026 /CNW/ - The following issues have been halted by CIRO:Company: Tilray Brands, Inc. TSX Symbol: TLRY All Issues: No Reason: Single Stock Circuit Breaker Halt Time (ET): 11:49:38 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.SOURCE Canadian Investment Regulatory Organization (CIRO) – Halts/Resumptions

Original: Canadian Investment Regulatory Organization Trading Halt - TLRY

Suspension de la négociation par l'Organisme canadien de réglementation des investissements - TLRYApril 22, 2026 12:03 PM
PR Newswire (Canada)

TORONTO, le 22 avril 2026 /CNW/ - L'OCRI a suspendu la négociation des titres suivants :Société : Tilray Brands, Inc. Symbole TSX : TLRY Les titres : Non Motif : Coupe-circuits pour titre individuel Heure de la suspension (HE) : 11 h 49:38 L'OCRI peut prendre la décision de suspendre (ou d'arrêter) temporairement les opérations à l'égard d'un titre d'une société cotée en bourse. Les arrêts des opérations sont mis en oeuvre afin d'assurer le bon fonctionnement d'un marché équitable. L'OCRI est l'organisme d'autoréglementation national qui surveille l'ensemble des courtiers en placement et l'ensemble des opérations effectuées sur les marchés des titres de capitaux propres et les marchés des titres de créance au Canada.SOURCE L’Organisme canadien de règlementation des investissements (OCRI) - Arrêts/Reprises

Original: Suspension de la négociation par l'Organisme canadien de réglementation des investissements - TLRY

From Axios today
Scoop: Trump set to reclassify marijuana soon
The Trump administration is expected to move to reclassify marijuana as soon as Wednesday, per an administration official familiar with the matter.
Why it matters: The move would make it easier to study medicinal applications of marijuana and could shore up support from influencers who support the research.
The move follows an executive order from the president last year to reclassify marijuana as a Schedule III drug, which is a years-long process.
How it works: Reclassifying marijuana eases U.S. Drug Enforcement Administration barriers to researching the drug's potential use cases.
It would not immediately legalize marijuana, nor would it affect the sentences of those incarcerated for possession.

Trump Administration is expected to move to reclassify as soon as Wednesday (today) 

From today's Cannabis Business Times

President Donald Trump politely asked on April 18 whether his administration would follow through on his [executive order](https://www.cannabisbusinesstimes.com/cannabis-rescheduling/news/15774497/trump-signs-order-to-reclassify-cannabis-to-schedule-iii) to reschedule cannabis, four months after he directed the Department of Justice (DOJ) to do so.

“You’re going to get the rescheduling done, right, please?” Trump asked. “Will you get the rescheduling done, please? Joe, they’re slow-walking me on rescheduling. OK, you’re going to get it done, right?”

$420$